Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 145040
Corporate User License Price USD 6000
Corporate User License Price INR 435120
Site License Price USD 4000
Site License Price INR 290080
Request a Quote

Report Title

Tetanus-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Tetanus-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Tetanus-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Tetanus-Pipeline Review, H1 2017



Executive Summary

Tetanus-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus-Pipeline Review, H1 2017, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 3, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tetanus-Overview

Tetanus-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tetanus-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tetanus-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Boryung Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

GlaxoSmithKline Plc

Green Cross Corp

Indian Immunologicals Ltd

Kaketsuken KK

LG Chem, Ltd.

Panacea Biotec Ltd

Prometheon Pharma LLC

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Ltd

Zydus Cadila Healthcare Ltd

Tetanus-Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole cell) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (whole-cell) + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVN-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-1107-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GC-3111A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Tetanus-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetanus vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VN-0105-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetanus-Dormant Projects

Tetanus-Discontinued Products

Tetanus-Product Development Milestones

Featured News & Press Releases

Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Tetanus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Tetanus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Tetanus-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Tetanus-Pipeline by Bharat Biotech International Ltd, H1 2017

Tetanus-Pipeline by Biological E Ltd, H1 2017

Tetanus-Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Tetanus-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Tetanus-Pipeline by GlaxoSmithKline Plc, H1 2017

Tetanus-Pipeline by Green Cross Corp, H1 2017

Tetanus-Pipeline by Indian Immunologicals Ltd, H1 2017

Tetanus-Pipeline by Kaketsuken KK, H1 2017

Tetanus-Pipeline by LG Chem, Ltd., H1 2017

Tetanus-Pipeline by Panacea Biotec Ltd, H1 2017

Tetanus-Pipeline by Prometheon Pharma LLC, H1 2017

Tetanus-Pipeline by Sanofi Pasteur SA, H1 2017

Tetanus-Pipeline by Serum Institute of India Ltd, H1 2017

Tetanus-Pipeline by Shantha Biotechnics Ltd, H1 2017

Tetanus-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Tetanus-Dormant Projects, H1 2017

Tetanus-Dormant Projects, H1 2017 (Contd..1), H1 2017

Tetanus-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Beijing Minhai Biotechnology Co Ltd, Bharat Biotech International Ltd, Biological E Ltd, Boryung Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, GlaxoSmithKline Plc, Green Cross Corp, Indian Immunologicals Ltd, Kaketsuken KK, LG Chem, Ltd., Panacea Biotec Ltd, Prometheon Pharma LLC, Sanofi Pasteur SA, Serum Institute of India Ltd, Shantha Biotechnics Ltd, Zydus Cadila Healthcare Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand